Drug Landscape ›
Dipyridamole 200 mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Alanine Aminotransferase Increased — 1 report (10%) Antinuclear Antibody Positive — 1 report (10%) Ascites — 1 report (10%) Aspartate Aminotransferase Increased — 1 report (10%) Blood Alkaline Phosphatase Increased — 1 report (10%) Blood Bilirubin Increased — 1 report (10%) Confusional State — 1 report (10%) Dementia — 1 report (10%) Drug Interaction — 1 report (10%) Fall — 1 report (10%)
Source database →
Dipyridamole 200 mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Dipyridamole 200 mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Dipyridamole 200 mg in United States?
Vastra Gotaland Region is the originator. The local marketing authorisation holder may differ — check the official source linked above.